FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean‐Baptiste Bachet, Thierry Lecomte et al.|New England Journal of Medicine|2018Cited by 2.8k
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean François Seitz, Florence Castan et al.|JAMA Oncology|2022Cited by 322
NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation TherapyNina N. Sanford, William A. Hall, Amol Narang et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 25
Inter-rater variability for the American Society of Anesthesiologists classification in patients undergoing hepato-pancreato-biliary surgery (MILESTONE-2): international survey among surgeons and anaesthesiologistsSimone Augustinus, Marc G. Besselink, Jasper P. Sijberden et al.|BJS Open|2024Cited by 7
Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract CancerDarren Cowzer, James J. Harding, Madison Darmofal et al.|JCO Precision Oncology|2025Cited by 3